Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, below expectations for 25%.
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump.
Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.
17h
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
1d
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Pharmaceutical Technology
4h
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
17h
on MSN
FDA says knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
1d
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
FiercePharma
21h
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
17h
on MSN
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
7d
on MSN
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
7d
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...
2d
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
5h
Premarket movers: FedEx, Eli Lilly, Nike
FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...
8h
on MSN
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback